Evidence-based insulin treatment in type 1 diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 86, Issue 1, 2009, Pages 1-10

  Jacobsen, Iben Brock ^a   Henriksen, J E ^a   Hother Nielsen, O ^a   Vach, W ^b   Beck Nielsen, H ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Evidence based; Insulin regimens; Literature review; Type 1 diabetes mellitus

Indexed keywords

HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; NEUTRAL INSULIN;

BEDTIME DOSAGE; CLINICAL TRIAL; COCHRANE LIBRARY; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG RESPONSE; EVIDENCE BASED MEDICINE; HEALTH SURVEY; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INFORMATION RETRIEVAL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MEDLINE; META ANALYSIS; QUALITY OF LIFE; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW;

DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 69849096122     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2009.05.020     Document Type: Review

References (70)

1. Alberti K.G., and Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation 13. Diabet. Med. 15 (1998) 539-553
2. Leslie R.D., and Pozzilli P. An introduction to new advances in diabetes 2. Diabetes Metab. Res. Rev. 18 Suppl. 1 (2002) S1-S6
3. DCCT. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N. Engl. J. Med. 329 (1993) 977-986
4. DCCT. Hypoglycemia in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes 46 (1997) 271-286
5. Home P.D. Intensive insulin therapy in clinical practice. Diabetologia 40 Suppl. 2 (1997) S83-S87
6. DCCT. Effect of intensive therapy on the development and progression of diabetic nephropathy in the diabetes control and complications trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int. 47 (1995) 1703-1720
7. Rizza R.A., Gerich J.E., Haymond M.W., Westland R.E., Hall L.D., Clemens A.H., et al. Control of blood sugar in insulin-dependent diabetes: comparison of an artificial endocrine pancreas, continuous subcutaneous insulin infusion, and intensified conventional insulin therapy 2. N. Engl. J. Med. 303 (1980) 1313-1318
8. Beck-Nielsen H., Olesen T., Mogensen C.E., Richelsen B., Olsen H.W., Ehlers N., et al. Effect of near normoglycemia for 5 years on progression of early diabetic retinopathy and renal involvement. Diabetes Res. 15 (1990) 185-190
9. Feldt-Rasmussen B., Mathiesen E.R., and Deckert T. Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes. Lancet 2 (1986) 1300-1304
10. The Kroc Collaborative Study Group. Blood glucose control and the evolution of diabetic retinopathy and albuminuria. A preliminary multicenter trial. The Kroc Collaborative Study Group. N. Engl. J. Med. 311 (1984) 365-372
11. Bak J.F., Nielsen O.H., Pedersen O., and Beck-Nielsen H. Multiple insulin injections using a pen injector versus insulin pump treatment in young diabetic patients 1. Diabetes Res. 6 (1987) 155-158
12. Bode B.W., Steed R.D., and Davidson P.C. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type I diabetes 9. Diabetes Care 19 (1996) 324-327
13. Dahl-Jorgensen K., Brinchmann-Hansen O., Hanssen K.F., Ganes T., Kierulf P., Smeland E., et al. Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study. Br. Med. J. (Clin. Res. Ed.) 293 (1986) 1195-1199
14. Bolli G.B., Di Marchi R.D., Park G.D., Pramming S., and Koivisto V.A. Insulin analogues and their potential in the management of diabetes mellitus 1. Diabetologia 42 (1999) 1151-1167
15. Hirsch I.B. Insulin analogues 10. N. Engl. J. Med. 352 (2005) 174-183
16. Kamal A.D., Dixon A.N., and Bain S.C. Safety and side effects of the insulin analogues 1. Expert. Opin. Drug Saf. 5 (2006) 131-143
17. Gale E.A. A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with Type 1 diabetes on intensified insulin therapy. The UK Trial Group. Diabet. Med. 17 (2000) 209-214
18. Home P.D., Lindholm A., and Riis A. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial. Diabet. Med. 17 (2000) 762-770
19. Colquitt J., Royle P., and Waugh N. Are analogue insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta-analysis 1. Diabet. Med. 20 (2003) 863-866
20. Plank J., Wutte A., Brunner G., Siebenhofer A., Semlitsch B., Sommer R., et al. A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes 1. Diabetes Care 25 (2002) 2053-2057
21. Weissberg-Benchell J., Antisdel-Lomaglio J., and Seshadri R. Insulin pump therapy: a meta-analysis 1. Diabetes Care 26 (2003) 1079-1087
22. Hoogma R.P., Hammond P.J., Gomis R., Kerr D., Bruttomesso D., Bouter K.P., et al. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial. Diabet. Med. 23 (2006) 141-147
23. DeVries J.H., Lindholm A., Jacobsen J.L., Heine R.J., and Home P.D. A randomized trial of insulin aspart with intensified basal NPH insulin supplementation in people with Type 1 diabetes 1. Diabet. Med. 20 (2003) 312-318
24. Grimm J.J., Haardt M.J., Thibult N., Goicolea I., Tchobroutsky G., and Slama G. Lifestyle, metabolic control and social implications of pump therapy in 54 routine type I diabetic patients. Diabete Metab. 13 (1987) 3-11
25. Raskin P., Guthrie R.A., Leiter L., Riis A., and Jovanovic L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 23 (2000) 583-588
26. Houtzagers C.M., Visser A.P., Berntzen P.A., van der S.H., van Maarschalkerweerd W.W., Heine R.J., et al. Multiple daily insulin injections improve self-confidence. Diabet. Med. 6 (1989) 512-519
27. Heller S.R., Amiel S.A., and Mansell P. Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. U. K. Lispro Study Group. Diabetes Care 22 (1999) 1607-1611
28. Tamas G., Marre M., Astorga R., Dedov I., Jacobsen J., and Lindholm A. Glycaemic control in type 1 diabetic patients using optimised insulin aspart or human insulin in a randomised multinational study. Diabetes Res. Clin Pract. 54 (2001) 105-114
29. Heller S.R., Colagiuri S., Vaaler S., Wolffenbuttel B.H., Koelendorf K., Friberg H.H., et al. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes. Diabet. Med. 21 (2004) 769-775
30. Zinman B., Tildesley H., Chiasson J.L., Tsui E., and Strack T. Insulin lispro in CSII: results of a double-blind crossover study. Diabetes 46 (1997) 440-443
31. Tsui E.Y., Chiasson J.L., Tildesley H., Barnie A., Simkins S., Strack T., et al. Counterregulatory hormone responses after long-term continuous subcutaneous insulin infusion with lispro insulin. Diabetes Care 21 (1998) 93-96
32. Launay B., Zinman B., Tildesley H.D., Strack T., and Chiasson J.L. Effect of continuous subcutaneous insulin infusion with lispro on hepatic responsiveness to glucagon in type 1 diabetes. Diabetes Care 21 (1998) 1627-1631
33. Garg S.K., Carmain J.A., Braddy K.C., Anderson J.H., Vignati L., Jennings M.K., et al. Pre-meal insulin analogue insulin lispro vs Humulin R insulin treatment in young subjects with type 1 diabetes. Diabet. Med. 13 (1996) 47-52
34. Leonard K., and Masatu M.C. Outpatient process quality evaluation and the Hawthorne Effect. Soc. Sci. Med. 63 (2006) 2330-2340
35. Johnston D. NICE guidance on type 1 diabetes in adults. Clin. Med. 4 (2004) 491-493
36. Lenhard M.J., and Reeves G.D. Continuous subcutaneous insulin infusion: a comprehensive review of insulin pump therapy. Arch. Intern. Med. 161 (2001) 2293-2300
37. Pickup J.C., and Sutton A.J. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet. Med. 25 (2008) 765-774
38. Pickup J., Mattock M., and Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 324 (2002) 705
39. Barnard K.D., Lloyd C.E., and Skinner T.C. Systematic literature review: quality of life associated with insulin pump use in Type 1 diabetes. Diabet. Med. 24 (2007) 607-617
40. Bode B., Weinstein R., Bell D., McGill J., Nadeau D., Raskin P., et al. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes 7. Diabetes Care 25 (2002) 439-444
41. Home P.D., Hallgren P., Usadel K.H., Sane T., Faber J., Grill V., et al. Pre-meal insulin aspart compared with pre-meal soluble human insulin in type 1 diabetes 3. Diabetes Res. Clin. Pract. 71 (2006) 131-139
42. DCCT. Influence of intensive diabetes treatment on quality-of-life outcomes in the diabetes control and complications trial. Diabetes Care 19 (1996) 195-203
43. Wiseman M.J., Saunders A.J., Keen H., and Viberti G. Effect of blood glucose control on increased glomerular filtration rate and kidney size in insulin-dependent diabetes. N. Engl. J. Med. 312 (1985) 617-621
44. Service F.J., Rizza R.A., Daube J.R., O'Brien P.C., and Dyck P.J. Near normoglycaemia improved nerve conduction and vibration sensation in diabetic neuropathy. Diabetologia 28 (1985) 722-727
45. Schmitz A., Christiansen J.S., Christensen C.K., Hermansen K., and Mogensen C.E. Effect of pump versus pen treatment on glycaemic control and kidney function in long-term uncomplicated insulin-dependent diabetes mellitus (IDDM). Dan. Med. Bull. 36 (1989) 176-178
46. Schiffrin A., and Belmonte M.M. Comparison between continuous subcutaneous insulin infusion and multiple injections of insulin. A one-year prospective study. Diabetes 31 (1982) 255-264
47. Moller A., Rasmussen L., Ledet T., Christiansen J.S., Christensen C.K., Mogensen C.E., et al. Lipoprotein changes during continuous subcutaneous insulin infusion in insulin-dependent diabetic patients. Scand. J. Clin. Lab. Invest. 46 (1986) 471-475
48. Marshall S.M., Home P.D., Taylor R., and Alberti K.G. Continuous subcutaneous insulin infusion versus injection therapy: a randomized cross-over trial under usual diabetic clinic conditions. Diabet. Med. 4 (1987) 521-525
49. Hermansen K., Moller A., Christensen C.K., Christiansen J.S., Schmitz O., Orskov H., et al. Diurnal plasma profiles of metabolite and hormone concentration in insulin-dependent diabetic patients during conventional insulin treatment and continuous subcutaneous insulin infusion. A controlled study. Acta Endocrinol. (Copenh) 114 (1987) 433-439
50. Helve E., Laatikainen L., Merenmies L., and Koivisto V.A. Continuous insulin infusion therapy and retinopathy in patients with type I diabetes. Acta Endocrinol. (Copenh) 115 (1987) 313-319
51. The Dusseldorf Study Group, Comparison of continuos subcutaneous insulin infusion and intensified conventional therapy in the treatment of Type 1 diabetes: a two-year randomized study, Diab. Nutr. Metab. 3 (2006) 203-212.
52. Ciavarella A., Vannini P., Flammini M., Bacci L., Forlani G., and Borgnino L.C. Effect of long-term near-normoglycemia on the progression of diabetic nephropathy. Diabetes Metab. 11 (1985) 3-8
53. Christensen C.K., Christiansen J.S., Schmitz A., Christensen T., Hermansen K., and Mogensen C.E. Effect of continuous subcutaneous insulin infusion on kidney function and size in IDDM patients: a 2 year controlled study. J. Diabet. Complications 1 (1987) 91-95
54. Chiasson J.L., Ducros F., Poliquin-Hamet M., Lopez D., Lecavalier L., and Hamet P. Continuous subcutaneous insulin infusion (Mill-Hill Infuser) versus multiple injections (Medi-Jector) in the treatment of insulin-dependent diabetes mellitus and the effect of metabolic control on microangiopathy. Diabetes Care 7 (1984) 331-337
55. Bending J.J., Viberti G.C., Watkins P.J., and Keen H. Intermittent clinical proteinuria and renal function in diabetes: evolution and the effect of glycaemic control. Br. Med. J. (Clin. Res. Ed.) 292 (1986) 83-86
56. Bangstad H.J., Kofoed-Enevoldsen A., Dahl-Jorgensen K., and Hanssen K.F. Glomerular charge selectivity and the influence of improved blood glucose control in type 1 (insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 35 (1992) 1165-1169
57. Valle D., Santoro D., Bates P., and Scarpa L. Italian multicentre study of intensive therapy with insulin lispro in 1184 patients with Type 1 diabetes. Diabetes Nutr. Metab. 14 (2001) 126-132
58. Schmauss S., Konig A., and Landgraf R. Human insulin analogue [LYS(B28), PRO(B29)]: the ideal pump insulin?. Diabet. Med. 15 (1998) 247-249
59. Renner R., Pfutzner A., Trautmann M., Harzer O., Sauter K., and Landgraf R. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group. Diabetes Care 22 (1999) 784-788
60. Raskin P., Holcombe J.H., Tamborlane W.V., Malone J.I., Strowig S., Ahern J.A., et al. A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump. J. Diabetes Complications 15 (2001) 295-300
61. Melki V., Renard E., Lassmann-Vague V., Boivin S., Guerci B., Hanaire-Broutin H., et al. Improvement of HbA1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps. Diabetes Care 21 (1998) 977-982
62. Lalli C., Ciofetta M., Del Sindaco P., Torlone E., Pampanelli S., Compagnucci P., et al. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diabetes Care 22 (1999) 468-477
63. Johansson U.B., Adamson U.C., Lins P.E., and Wredling R.A. Improved blood glucose variability, HbA1c insuman Infusat and less insulin requirement in IDDM patients using insulin lispro in CSII. The Swedish Multicenter Lispro Insulin Study. Diabetes Metab. 26 (2000) 192-196
64. Jehle P.M., Fussgaenger R.D., Kunze U., Dolderer M., Warchol W., and Koop I. The human insulin analog insulin lispro improves insulin binding on circulating monocytes of intensively treated insulin-dependent diabetes mellitus patients. J. Clin. Endocrinol. Metab. 81 (1996) 2319-2327
65. Jacobs M.A., Keulen E.T., Kanc K., Casteleijn S., Scheffer P., Deville W., et al. Metabolic efficacy of preprandial administration of Lys(B28), Pro(B29) human insulin analog in IDDM patients. A comparison with human regular insulin during a three-meal test period. Diabetes Care 20 (1997) 1279-1286
66. Holleman F., Schmitt H., Rottiers R., Rees A., Symanowski S., and Anderson J.H. Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. The Benelux-UK Insulin Lispro Study Group. Diabetes Care 20 (1997) 1827-1832
67. Daniels A.R., Bruce R., and McGregor L. Lispro insulin as premeal therapy in type 1 diabetes: comparison with Humulin R. N. Z. Med. J. 110 (1997) 435-438
68. Colombel A., Murat A., Krempf M., Kuchly-Anton B., and Charbonnel B. Improvement of blood glucose control in Type 1 diabetic patients treated with lispro and multiple NPH injections. Diabet. Med. 16 (1999) 319-324
69. Ciofetta M., Lalli C., Del Sindaco P., Torlone E., Pampanelli S., Mauro L., et al. Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime. Diabetes Care 22 (1999) 795-800
70. Annuzzi G., Del Prato S., Arcari R., Bellomo D.A., Benzi L., Bruttomesso D., et al. Preprandial combination of lispro and NPH insulin improves overall blood glucose control in type 1 diabetic patients: a multicenter randomized crossover trial. Nutr. Metab. Cardiovasc. Dis. 11 (2001) 168-175